Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy
28 mar 2019
INFORMAZIONI SU QUESTO ARTICOLO
Categoria dell'articolo: Review
Pubblicato online: 28 mar 2019
Pagine: 148 - 158
Ricevuto: 20 lug 2018
Accettato: 05 set 2018
DOI: https://doi.org/10.2478/raon-2019-0018
Parole chiave
© 2019 Tomaz Makovec, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1

Figure 2

Polymorphisms of transporters that influence the efficacy of platinum drugs
Protein | Gene | Genetic polymorphisms or expression level (EL) that influences the outcome of platinum-based therapy |
---|---|---|
Uptake of platinum drugs | ||
OCT1 | c.181C > T, c.480C > G, c.1022C > T, c.1222A > G, c.1390G > A, c.1463G > T | |
OCT2 | c.160C > T, c.481 T > C, c.493A > G, c.495G > A, c.808G > T, c.890C > G, c.1198C > T, c.1294A > C | |
OCT3 | EL | |
CTR1 | rs10981694 A>C | |
CTR2 |
Polymorphisms of DNA-platinum drug adducts repairing enzymes
Protein | Gene | Polymorphisms |
---|---|---|
DNA-adduct repair system | ||
ERCC1 | c.8092C>A, c.C354T | |
XRCC1 | c.C580T, c.A1196G | |
XRCC3 | p.Thr241Met, c.C241T | |
XPD | p.Lys751Gln, c.A2251C, c.C2133T | |
XPG | c.T242C | |
XPA | 5’UTR |